A Randomized, Open-label Study of Dapagliflozin in Patients with Type 2 Diabetes Admitted with Acute Heart Failure

About this Study

This study is for patients with Type II diabetes and who have come to the hospital with symptoms of Acute Heart Failure (AHF).  It is designed to compare usual care to using dapagliflozin along with the usual care to treat AHF in hospitalized patients. Dapagliflozin is an FDA approved medication that is already used to help patients manage Type II Diabetes.

Sponsor Protocol ID:ESR-19-14538
IRB Number:2020-0133
Actively Enrolling
Phase 3
January 11, 2022
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
  • Age of 18 years or older
  • Admitted to hospital within 24 hrs
  • Use of IV loop diuretic therapy with in hospital
  • History of Type 2 diabetes or new hemoglobin A1c greater than 6.5% at hospital admission

Exclusion Criteria
  • Type 1 diabetes
  • Glucose less than 80mg/dl
  • Systolic blood pressure less than 90mmHG
  • Need for IV inotropic therapy
  • Pregnant or nursing women
  • Severe anemia
  • History of diabetic ketoacidosis
  • Severe liver problems

Categories Click category to view its trials.
Heart Health
Participating Locations
Emergency Room (Adult) - UMMC
Pavilion - UMMC
University Heart - UMMC
Contact Information
Contact Name: Theresa Hutson
Phone Number: 601-815-8702
Email: thutson@umc.edu
Principal Investigator:Gabriel Hernandez
How to participate in our Clinical Trials